| 18th week of 2012 patent applcation highlights part 47 |
| Patent application number | Title | Published |
|---|
| 20120107216 | HYDROCHLORINATION HEATER AND RELATED METHODS THEREFOR - The systems and method of the invention involve hydrochlorination by providing feed streams with suitable reaction conditions through reactant stream conditioning systems and components. The conditioning systems facilitate vaporization of silicon tetrachloride in gaseous hydrogen to produce a reactant stream comprising hydrogen that is saturated with silicon tetrachloride. Saturation can be effected without the use of superheated steam or hot oil by utilizing saturated steam that is less than about 15 bar. The saturated reactant stream can be further heated to reaction conditions that effect conversion to trichlorosilane. | 2012-05-03 |
| 20120107217 | METHOD FOR PRODUCING OLIGOHALOGEN SILANES - The invention relates to a method for producing oligohalogen silanes, selected from oligohalogen silanes of the general formulas (1) and (2): Si | 2012-05-03 |
| 20120107218 | PRODUCTION METHOD OF SILICON CARBIDE CRYSTAL, SILICON CARBIDE CRYSTAL, AND PRODUCTION DEVICE OF SILICON CARBIDE CRYSTAL - A production method of a SiC crystal includes the following steps. That is, there is prepared a production device including a crucible and a heat insulator covering an outer circumference of the crucible. A source material is placed in the crucible. A seed crystal is placed opposite to the source material in the crucible. The silicon carbide crystal is grown by heating the source material in the crucible for sublimation thereof and depositing resultant source material gas on the seed crystal. The step of preparing the production device includes the step of providing a heat dissipation portion, which is constituted by a space, between the heat insulator and an outer surface of the crucible at a side of the seed crystal. | 2012-05-03 |
| 20120107219 | APPARATUS AND METHOD FOR PRODUCING PURIFIED HYDROGEN GAS BY A PRESSURE SWING ADSORPTION PROCESSES - The invention relates to a method and an apparatus for producing purified hydrogen gas by a pressure swing adsorption process. Further the invention relates to detecting an operating life of adsorbents in a adsorption tower. The method and the apparatus have a gas supply unit for adding an inert gas to an unpurified hydrogen gas and a detector for measuring an inert gas in a purified hydrogen gas discharged from the adsorption tower. | 2012-05-03 |
| 20120107220 | DEVICE FOR MANUFACTURING ALIGNED CARBON NANOTUBE ASSEMBLY - Provided is a production apparatus ( | 2012-05-03 |
| 20120107221 | METHOD FOR THE SYNTHESIS OF CARBON NANOTUBES ON LONG PARTICULATE MICROMETRIC MATERIALS - The invention relates to a method for the synthesis of carbon nanotubes on the surface of a material. The invention more particularly relates to a method for the synthesis of carbon nanotubes (or CNT) at the surface of a material using a carbon source comprising acetylene and xylene, and a catalyst containing ferrocene. The method of the invention has the advantage, amongst others, of enabling the continuous synthesis of nanotubes when desired. Also, the method of the invention is carried out at temperatures lower than those of known methods and on materials on which the growth of carbon nanotubes is difficulty reproducible and/or difficulty homogenous in terms of CNT diameter and density (number of CNT per surface unit). Said advantages, amongst others, make the method of the invention particularly useful at the industrial level. The invention also relates to materials that can be obtained by said method and to the use thereof in all the known application fields of carbon nantubes, in particular as a reinforcement for preparing structural and functional composite materials. | 2012-05-03 |
| 20120107222 | EXPANDED GRAPHITE SHEET - An object is to provide an expanded graphite sheet at the use stage that can prevent can prevent degradation in product quality and deterioration in product yield by inhibiting the expanded graphite sheet from containing impurities even when the expanded graphite sheet is actually used. | 2012-05-03 |
| 20120107223 | METHOD FOR PRODUCING HYDROGEN FLUORIDE - The present invention provides a novel method for producing hydrogen fluoride, which is capable of using various calcium fluoride sources and preventing a second pasty state from occurring, effectively. | 2012-05-03 |
| 20120107224 | Methods Of Making A Niobium Metal Oxide and Oxygen Reduced Niobium Oxides - Methods to at least partially reduce a niobium oxide are described wherein the process includes mixing the niobium oxide and niobium powder to form a powder mixture that is then heat treated to form heat treated particles which then undergo reacting in an atmosphere which permits the transfer of oxygen atoms from the niobium oxide to the niobium powder, and at a temperature and for a time sufficient to form an oxygen reduced niobium oxide. Oxygen reduced niobium oxides having high porosity are also described as well as capacitors containing anodes made from the oxygen reduced niobium oxides. | 2012-05-03 |
| 20120107225 | METHOD FOR PRODUCING TITANIUM-BASED MATERIAL FOR BIO-IMPLANT HAVING ZINC FUNCTIONAL GROUP GIVEN THERETO, AND TITANIUM-BASED MATERIAL FOR BIO-IMPLANT - The present invention provides a titanium-based material for a bio-implant having a fourth generation function given thereto, by a method for producing a titanium-based material for a bio-implant having a zinc functional group, wherein the method comprises a soaking step in which a base material made of titanium and an alloy thereof is soaked in an alkali solution containing a zinc hydroxide complex. | 2012-05-03 |
| 20120107226 | GAS-ASSISTED HYDROGEN DESORPTION METHOD AND APPARATUS FOR HYDROGEN STORAGE MATERIAL - The present invention relates to a gas-assisted hydrogen desorption method and apparatus, and more particularly, to a method for desorbing hydrogen from a self-catalyzing hydrogen storage material that is assisted by a carrier gas so as to further enable the portion of hydrogen containing in the self-catalyzing hydrogen storage material that can not be desorbed by conventional hydrogen desorption methods to be desorbed, and thus increase the amount of hydrogen to be released from the a self-catalyzing hydrogen storage material. | 2012-05-03 |
| 20120107227 | PROCESS FOR THE PRODUCTION OF HYDROGEN BY STEAM REFORMING AN OIL CUT WITH OPTIMIZED STEAM PRODUCTION - The present invention describes a process for the production of hydrogen by steam reforming an oil cut using a hot vector gas, in which the steam produced by the process is used in its entirety in said process, a first portion of the steam being introduced as a mixture with the feed, and the second portion supplying the steam turbine driving the compressor for pressurizing the hot vector gas. | 2012-05-03 |
| 20120107228 | HYDROGEN GAS GENERATING MEMBER AND HYDROGEN GAS PRODUCING METHOD THEREFOR - There is provided a hydrogen gas generating member which safely facilitates the hydrogen gas generation reaction by bringing an Al alloy which is subjected to rolling treatment or powdering treatment into contact with water. | 2012-05-03 |
| 20120107229 | NOVEL NANO-PROBES FOR MOLECULAR IMAGING AND TARGETED THERAPY OF DISEASES - The present inventions relate to compositions and methods for imaging and treating atherosclerotic diseases, pathogen infections, and tumors by administering actively targeting magnetic nanoparticles. In particular, the present inventions provide new types of targeting ligands attached to magnetic nanoparticles for magnetic resonance imaging. The use of these targeted magnetic nanoparticles is contemplated as a means to treat atherosclerotic diseases, including but not limited to inhibiting and removing atherosclerotic plaques. Further, actively targeting magnetic nanoparticles are contemplated for use with multiple labels for use in nuclear medicine imaging, computed tomography (CT) techniques and other types of imaging for medical and research applications. | 2012-05-03 |
| 20120107230 | Treatment of Hyperproliferative Diseases with Vinca Alkaloid N-Oxide Analogs - The present invention relates to vinca alkaloid and analog N-oxides having activity for treating hyperproliferative disorders. Further, the invention relates to pharmaceutical compositions and methods of using vinca alkaloid and analog N-oxides, alone or in combination with one or more other active agents or treatments, to treat hyperproliferative disorders. | 2012-05-03 |
| 20120107231 | METALLOPROTEINASE BINDING PROTEINS - Proteins that bind to matrix metalloproteinase 14 and methods of using such proteins are described. | 2012-05-03 |
| 20120107232 | KIT FOR PREPARING A RADIOLABELED LIPOSOME AND A METHOD USING THE SAME - A kit for preparing a radiolabeled liposome is provided, the kit including a liposome suspension and a radionuclide, wherein the liposome suspension includes a conjugate with a structure of [chelator-hydrophilic polymer-lipid]. A method for preparing a radiolabeled liposome using the kit is also disclosed herein, thereby the radiolabeled liposome being produced with the conjugate connected to the surface therein. The advantages of the present disclose such as simple, convenient and without purifying for the produced radiolabeled liposome are thus achieved. Further, the produced radiolabeled liposome has a high specific activity and a high sensitivity and suits for the clinical use. | 2012-05-03 |
| 20120107233 | Cytotoxicity Mediation of Cells Evidencing Surface Expression of CD44 - This invention relates to the diagnosis and treatment of cancerous diseases, particularly to the mediation of cytotoxicity of tumor cells; and most particularly to the use of cancerous disease modifying antibodies (CDMAB), optionally in combination with one or more chemotherapeutic agents, as a means for initiating the cytotoxic response. The invention further relates to binding assays which utilize the CDMAB of the instant invention. | 2012-05-03 |
| 20120107234 | Pan-HER Antibody Composition - The present invention is directed to improved therapeutics against receptors within the EGFR/ErbB/HER family that more broadly interfere with multiple members of the HER family (pan-HER inhibition). More particularly, the invention is directed to the use of antibody compositions for human cancer therapy. In vitro studies have shown that the antibody compositions of the invention targeting multiple HER family receptors are superior to antibody compositions targeting only one HER family receptor. | 2012-05-03 |
| 20120107235 | Alpha-Fetoprotein Immu31 Antibodies and Fusion Proteins and Methods of Use Thereof - The present invention provides humanized, chimeric and human anti-alpha-fetoprotein antibodies, fusion proteins, and fragments thereof. The antibodies, fusion proteins, and fragments thereof, as well as combinations with other suitable antibodies, are useful for the treatment and diagnosis of hepatocellular carcinoma, hepatoblastoma, germ cell tumors carcinoma and other AFP-producing tumors. | 2012-05-03 |
| 20120107236 | LIVER- RECEPTOR IMAGING INJECTION, DISPENSING METHOD AND PHARMACEUTICAL COMPOSITION THEREOF - The present invention is related to a pharmaceutical composition for a liver-receptor imaging injection, the pharmaceutical composition including a bi-functional compound which has a ASGPR specificity, wherein the bi-functional compound includes a backbone of alpha-amino acid (or the derivatives thereof) and a poly-galactosamine chain (or a poly-lactose chain) connected to the alpha-amino acid. Thereby, the pharmaceutical composition can quantify potential of liver storage ability and evaluate severity of the course of liver disease. A liver-receptor imaging injection using the same and the one-step dispensing method thereof are also provided to improve defects of iodine-labeled and overcome disadvantages of the reduced labeling-yield and the instability after autoclave sterilization. | 2012-05-03 |
| 20120107237 | ARG-GLY-ASP-CONJUGATED ALPHA-MELANOCYTE STIMULATING HORMONE HYBRID PEPTIDE FOR USE IN DIAGNOSING AND TREATING MELANOMA, INCLUDING METASTATIC MELANOMA AND METHODS RELATED TO SAME - The present invention is directed to novel non-invasive diagnostic and therapeutic tools/compounds comprising a hybride cyclic peptide which utilizes a cyclic peptide chelating group wherein the compound binds to a MSH receptor to image and treat cancers, especially, melanoma, including metastatic melanoma in vivo. The present invention represents a clear advance in the art which presently relies on tissue biopsy for diagnoses of these cancers. The novel imaging probes are capable of detecting cancerous melanoma cells, as well as their metastatic spread in tissues. This represents a quantum step forward in the diagnosis and treatment of melanoma, including metastatic melanoma using non-invasive molecular imaging techniques. The novel probes of the present invention will also be useful to initiate therapy for melanoma as well as monitor patients response to chemotherapy treatments and other interventions or therapies used in the treatment of melanoma/metastatic melanoma. Compound according to the present invention may be used as diagnostic tools for a number of conditions and diseases states as well as therapeutic agents for treating such conditions and disease states. | 2012-05-03 |
| 20120107238 | COMPOUND CONTAINING A CARBON OR AN OXYGEN ISOTOPE, PREPARATION AND USE THEREOF, AND COMPOSITION COMPRISING THEREOF - The present disclosure relates to a compound comprising at least one of a carbon or an oxygen isotope and a process for preparing the compound. The process comprises irradiating a compound comprising at least one of a carbon or an oxygen atom using photons or particles having an energy in the range of 20 MeV-430 MeV. The carbon and/or the oxygen atom is then allowed to be converted into a carbon and/or an oxygen positron nuclide through a photonuclear reaction. Provided that the molecular structure of the compound is not disrupted, the compound comprising the carbon and/or the oxygen isotope is prepared. The compound may be used in positron and/or other nuclide imaging to obtain a distribution and/or metabolic image of the compound in a human and/or animal body. | 2012-05-03 |
| 20120107239 | Precursor of Molecular Probe for Pancreatic Islet Imaging and Use of the Same - A precursor of a molecular probe for imaging of pancreatic islets is a compound expressed as the following formula (I): | 2012-05-03 |
| 20120107240 | Probes and methods of melanoma imaging - Embodiments of the present disclosure provide for labeled probes such as a 3- | 2012-05-03 |
| 20120107241 | Particles for Inhalation Having Sustained Release Properties - The invention generally relates to a method for pulmonary delivery of therapeutic, prophylactic and diagnostic agents to a patient wherein the agent is released in a sustained fashion, and to particles suitable for use in the method. In particular, the invention relates to a method for the pulmonary delivery of a therapeutic, prophylactic or diagnostic agent comprising administering to the respiratory tract of a patient in need of treatment, prophylaxis or diagnosis an effective amount of particles comprising a therapeutic, prophylactic or diagnostic agent or any combination thereof in association with a charged lipid, wherein the charged lipid has an overall net charge which is opposite to that of the agent upon association with the agent. Release of the agent from the administered particles occurs in a sustained fashion. | 2012-05-03 |
| 20120107242 | NUCLEIC ACID-MEDIATED SHAPE CONTROL OF NANOPARTICLES FOR BIOMEDICAL APPLICATIONS - Embodiments of a method for nucleic acid-mediated control of a nanoparticle shape are disclosed. In some embodiments, one or more nucleic acid oligomers are adsorbed to a metal nanoseed, and additional metal is deposited onto the nanoseed to produce a shaped nanoparticle. In certain embodiments, the nanoseed is gold and the oligomers are 5-100 nucleotides in length. The nanoparticle shape is determined at least in part by the nucleic acid sequence of the oligomer(s). Shaped nanoparticles produced by embodiments of the method include nanoflowers, nanospheres, nanostars, and nanoplates. Embodiments for using the shaped nanoparticles also are disclosed. | 2012-05-03 |
| 20120107243 | PEPTIDE-MEDIATED NON-COVALENT DELIVERY OF ACTIVE AGENTS ACROSS THE BLOOD-BRAIN BARRIER - The peptides described herein can function as carrier peptides. These peptides can associate with (e.g., non-covalently bind) biologically active molecules or imaging agents to transport the biologically active molecules or imaging across the blood-brain barrier. In some cases, such transport may increase the effectiveness of the biological molecules or imaging agents. | 2012-05-03 |
| 20120107244 | MONOMERIC VARIANTS OF THE TETRAMERIC eqFP611 - Monomeric eqFP611 variants exhibit red fluorescent properties and DNA encoding monomeric eqFP611 variants. | 2012-05-03 |
| 20120107245 | DENTAL COMPOSITION FOR DETECTION OF CARIOUS TISSUE, DETECTION METHOD - A dental composition and method for detecting carious tissue on the surface of a tooth, and the use of the dental composition to manufacture a remedy for detection of carious tissue. The dental composition can comprise an aqueous solution of 1) at least one acidic compound, 2) at least one salt of said acidic compound, 3) at least one indicator that generates a detectable signal when said solution reaches a particular pH value that is less than 5.5; wherein 1) and 2) are selected such that the aqueous solution has a pH of less than that particular pH value where the indicator generates the signal. The method can comprise the steps of 1) providing the above mentioned dental composition, 2) applying said composition to the surface of said tooth, and 3) measuring the amount of time required for the composition to change color. | 2012-05-03 |
| 20120107246 | METHOTREXATE-MODIFIED NANOPARTICLES AND RELATED METHODS - Methotrexate-modified nanoparticles that target tumors, compositions that include the nanoparticles, methods of imaging tissues using the nanoparticles, and methods for treating tissues using the nanoparticles. | 2012-05-03 |
| 20120107247 | Proteins Expressed by Mycobacterium Tuberculosis and not by BCG and their Use as Diagnostic Reagents and Vaccines - The present invention is directed to reagents useful for generating immune responses to | 2012-05-03 |
| 20120107248 | IMAGING GASTROINTESTINAL VOLUMES AND MOTILITY - This disclosure relates to contrast agents and compositions comprising the same that are capable of blocking the hydrogen/potassium adenosine triphosphatase enzyme system, and more particularly to the use of such compositions for imaging stomach and colon volume and motility. | 2012-05-03 |
| 20120107249 | Diagnostic Imaging Contrast Agents with Extended Blood Retention - The present invention relates to contrast agents for diagnostic imaging with prolonged blood retention. In particular, this invention relates to novel compounds that are characterized by an image enhancing moiety (IEM); a protein plasma binding moiety (PPBM); and a blood half-life extending moiety (BHEM). This invention also relates to pharmaceutical compositions comprising these compounds and to methods of using the compounds and compositions for blood half-life extension and contrast enhancement of diagnostic imaging. | 2012-05-03 |
| 20120107250 | ABUSE-PROOFED DOSAGE FORM - An abuse-proofed, thermoformed dosage form containing, in addition to one or more active ingredients with abuse potential optionally together with physiologically acceptable auxiliary substances, at least one synthetic or natural polymer with a breaking strength of at least 500 N and to a process for the production thereof. | 2012-05-03 |
| 20120107251 | OREGANO ORAL CARE COMPOSITIONS AND METHODS OF USE THEREOF - A multi-benefit oral composition is provided. The oral composition is efficacious as an antibacterial, antiplaque, anti-inflammatory, anti-oxidant, and anti-halitosis oral composition. The active ingredient has one or more active compounds from an extract of oregano. The oral composition can be in the form of a mouth rinse; a dentifrice, including toothpaste, gels, powders; animal products; a film; or confectionaries, such as lozenges, and the like. Methods of making and using the oral composition are also provided. | 2012-05-03 |
| 20120107252 | METHOD FOR FORMING CYCLODEXTRIN POLYMER AND LIPOPHILIC COMPOUND EMULSIONS, RESULTING EMULSIONS, AND COMPOSITIONS INCLUDING SAID EMULSIONS - The present invention relates to a method for preparing a cyclodextrin polymer and/or a hydrophilic polymer emulsion having cyclodextrins as well as lipophilic compounds, the emulsions having a remarkable stability. In particular, the method includes: (i) adding a lipophilic compound into an aqueous solution of a cyclodextrin unit polymer or hydrophilic polymer having cyclodextrins; (ii) forming an emulsion from the mixture resulting from step (i). The invention also relates to the resulting emulsions, i.e. stabilized emulsions by a non-covalent and non-crystalline inclusion complex consisting of (i) a cyclodextrin unit polymer or a hydrophilic polymer having cyclodextrins and (ii) a lipophilic compound. The invention also relates to the use of said emulsions in the cosmetic, pharmaceutical and/or agri-food fields. | 2012-05-03 |
| 20120107253 | SUNSCREEN FORMULATIONS USING NATURAL OCEANIC CLAY (aka Marine Glacial Clay) - Sunscreen formulations use the Natural Oceanic Clay when combined with sunscreen actives such as zinc oxide, can provide significant enhancement in absorbance of UVA, UVB, and UVC, with increased SPF and PFA readings. | 2012-05-03 |
| 20120107254 | Long Wear Topical Composition - This disclosure relates to a long wear topical composition for keratinous surface. The composition includes at least one coupling agent having at least two reactive functional groups and at least one performance ingredient. | 2012-05-03 |
| 20120107255 | PHOTOSTABILIZATION OF CHOLECALCIFEROL WITH ALKOXYCRYLENE COMPOUNDS - A method of reducing photodegradation of cholecalciferol when exposed to UV radiation in a composition containing cholecalciferol comprising combining with cholecalciferol a compound of formula (I) in an amount effective to quench excited state energy from cholecalciferol and transfer the excited state energy from cholecalciferol to the compound of formula (I), | 2012-05-03 |
| 20120107256 | Personal Care Emulsions Comprising Waxy Materials And Organopolysiloxanes - The invention provides an aqueous emulsion for use in a personal care, health care or household care composition. This emulsion comprises at least 1% by weight of a waxy material having a melting point of at least 10.5° C. and at least 1% by weight of an organopolysiloxane which is not miscible with the waxy material. The emulsion also contains an oil having a melting point below 10° C., the oil being miscible with the waxy material when melted and being present in a weight ratio of oil to waxy material in the range 5:95 to 95:5. This permits to obtain stable emulsion at low temperature. | 2012-05-03 |
| 20120107257 | PIGMENTARY AQUEOUS DISPERSION AND COSMETIC USES THEREOF - The invention relates to an aqueous dispersion comprising at least one pigment and polyvinylpyrrolidone with a weight average molecular weight of less than 40,000 g/mol, its preparation method and its cosmetic uses. | 2012-05-03 |
| 20120107258 | OMEGA-CYCLOHEXYLALKAN-1-OLES AND USE THEREOF AS ANTIMICROBIAL ACTIVES TO COMBAT BODY ODOR - The present invention relates to antimicrobially active ω-cyclohexylalkan-1-ales of the following formula (I), to a method for producing said compounds and to the use thereof as antimicrobial agents for treating body odor, | 2012-05-03 |
| 20120107259 | METHOD TO IMPROVE SKIN AND HAIR FRAGRANCE RETENTION FROM PERSONAL CARE COMPOSITIONS - A personal care composition and a method of using personal care compositions which results in increased fragrance retention when such compositions are applied to a keratin surface including hair and skin. The personal care compositions contain a quaternary ammonium compound, one or more fragrances, and a personal care acceptable carrier. | 2012-05-03 |
| 20120107260 | DEODORANT COMPOSITIONS - This invention relates to deodorant compositions containing polytrimethylene ether glycol homo- and copolymers and/or polytrimethylene glycol ester(s) in a variety of physical forms. In at least one embodiment, the polytrimethylene ether glycol homo- and copolymers and/or polytrimethylene glycol ester(s) can be made from monomers (e.g., 1,3-propanediol) obtained from renewable resources, and can thus be more environmentally friendly than conventional deodorant compositions in terms of manufacture, use and disposal. | 2012-05-03 |
| 20120107261 | COSMETIC COMPOSITIONS HAVING SUSPENSIONS OF SILVER SALTS - An anhydrous cosmetic or dermatological preparation includes an aqueous suspension of at least one silver halide having a water content of up to 90 wt. %, relative to the total mass of the suspension, applied to a carrier, in combination with one or more passivating agents selected from the group of phyllosilicates and/or talc, one or more antiperspirant active ingredients, and perfume. | 2012-05-03 |
| 20120107262 | COMPOSITION AND METHOD FOR LEVELLING HAIR COLOUR - The present invention relates to a composition and a method of levelling hair colour, especially lighter coloured hair or including lightened streaks or bleached streaks or bleached as a whole and after certain period of time contrast—difference in colour—between the re-growth and formerly lightened parts is clearly visible. The first objective of the present invention is an aqueous composition for levelling hair colour comprising at least one fatty acid salt, preferably an in-situ formed ammonium salt, and one or more anionic surfactants at a total concentration between 5 and 30% by weight, calculated to total of the composition, and has a pH between 5 and 12. Furthermore, use of the composition for levelling hair colour and a method of levelling hair colour are disclosed. | 2012-05-03 |
| 20120107263 | LONG-WEAR, WATERPROOF AND WASHABLE MASCARA COMPOSITION - The present invention is directed to long wear, washable and waterproof eye makeup composition containing: (a) at least one polyamine; (b) at least one oil-soluble polar modified polymer; (c) water; (d) at least one non-volatile oil capable of solublizing the oil-soluble polar modified polymer; (d) at least one volatile solvent; (e) optionally, at least one colorant; and (f) optionally, at least one wax, wherein the composition does not require a latex film former or surfactant/emulsifier. | 2012-05-03 |
| 20120107264 | NUCLEIC ACID DELIVERY COMPOUNDS - Polymers including two or more different recurring units are disclosed herein. Also disclosed herein are methods of using such polymers to deliver nucleic acids to a cell. | 2012-05-03 |
| 20120107265 | METHOD FOR PRODUCING MONOTERPENE AND MONOTERPINOID COMPOUNDS AND USE THEREOF - In various embodiments, the present disclosure provides a method and enzyme for forming various compounds, such as monoterpenes and monoterpenoid compounds. In a specific example, the present disclosure provides a method for producing one or more of (−)-ipsdienol, (−)-ipsenol, ipsenone, and ipsdienone. The present disclosure also provides methods of using compounds formed from the disclosed method and enzyme. | 2012-05-03 |
| 20120107266 | COMPOSITIONS AND METHODS FOR ATTRACTING NOCTUID MOTHS - The invention provides compositions for attracting noctuid moths, which include at least one pheromone and at least one synergist. The synergist is a naturally-occurring phytochemical compound. The synergist is preferably β-caryophyllene, iso-caryophyllene, α-humulene, or combinations thereof. The invention also provides traps containing the composition for attracting noctuid moths, and methods for attracting, capturing, killing or sterilizing noctuid moths using the composition. | 2012-05-03 |
| 20120107267 | INTERLEUKIN-21 VARIANTS HAVING ANTAGONISTIC BINDING TO THE IL-21 RECEPTOR - The invention relates to isolated IL-21 variant peptides having antagonistic binding to the common gamma chain (yC) of the IL-21 receptor, to pharmaceutical compositions comprising said peptides and to the use of said peptides in therapy. | 2012-05-03 |
| 20120107268 | LYMPH NODE-TARGETING NANOPARTICLES - Provided are nanoparticles comprising heparin, chitosan, and at least one immunomodulatory agent, e.g. a cytokine. The cytokine can be selected from the group consisting of TNF, IL-12, IL-2, IL-23, IL-1α, IL-10, IL-18, and combinations thereof. Further provided are methods of making a nanoparticle comprising mixing a first composition comprising heparin with a second composition comprising chitosan in the presence of at least one cytokine to form a third composition. Further provided are methods of modulating an immune response comprising co-administering to a subject an antigen or vaccine with nanoparticles comprising heparin, chitosan, and at least one cytokine. | 2012-05-03 |
| 20120107269 | THIOPHENE DERIVATIVES - Disclosed is a compound of formula (I), | 2012-05-03 |
| 20120107270 | Immunocytokines In Combination With Anti-ErbB Antibodies For The Treatment Of Cancer - This invention relates to the treatment of cancer using anti-ErbB antibodies, such as cetuximab or trastuzumab, in combination with antibody-interleukin 2 (IL2) conjugates which target tenascin-C. | 2012-05-03 |
| 20120107271 | ETHYNYL-SUBSTITUTED PYRIDINE AND PYRIMIDINE DERIVATIVES AND THEIR USE IN TREATING VIRAL INFECTIONS - The present invention provides compounds of Formula (I): (Chemical formula should be inserted here as it appears on abstract in paper form) (I) and tautomers, isomers, and esters of said compounds, and pharmaceutically acceptable salts, solvates, and pro-drugs of said compounds, wherein each of R, R | 2012-05-03 |
| 20120107272 | SYNTHETIC METHODS AND DERIVATIVES OF TRIPHOSPHATE OLIGONUCLEOTIDES - The invention features a oligonucleotide of formula I, or pharmaceutically acceptable salts, or prodrugs thereof: | 2012-05-03 |
| 20120107273 | NEW PIPERAZINE COMPOUND AND USE THEREOF AS A HCV POLYMERASE INHIBITOR - The present invention relates to a compound represented by the following formula [I] | 2012-05-03 |
| 20120107274 | 2'-FLUORO SUBSTITUTED CARBA-NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT - Provided are methods for treating Orthomyxoviridae virus infections by administering ribosides, riboside phosphates and prodrugs thereof, of Formula I: | 2012-05-03 |
| 20120107275 | FUSED HETEROCYCLIC DERIVATIVES AND METHODS OF USE - Selected compounds are effective for prophylaxis and treatment of diseases, such as HGF mediated diseases. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable salts thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving, cancer and the like. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes. | 2012-05-03 |
| 20120107276 | Anti-Arenaviral Compounds - Described herein are 4-methyl-piperazine-1-carbothioic acid amide derivatives and analogs, as well as compositions containing the same, for the treatment or prophylaxis of viral infections and diseases associated therewith, particularly those viral infections and associated diseases caused by hemorrhagic fever viruses, such as Arenaviruses. | 2012-05-03 |
| 20120107277 | USE OF THE COMBINATION OF TERIFLUNOMIDE AND INTERFERON BETA FOR TREATING MULTIPLE SCLEROSIS - This invention is related to the use of the combination of teriflunomide and interferon beta thereof, for the preparation of a medicament for use in treating multiple sclerosis. | 2012-05-03 |
| 20120107278 | ABBREVIATED HCV THERAPY FOR HCV INFECTED PATIENTS WITH IL28B C/C GENOTYPE - Disclosed herein is a method for administering an abbreviated hepatitis C virus (HCV) treatment regimen for an HCV-infected, rs12979860 single nucleotide polymorphism (SNP) (C/C) patient, which comprises: administering to said patient an effective amount of each of a direct-acting antiviral, pegylated interferon alfa-2a, and ribavirin; wherein the abbreviated HCV treatment regimen is less than 48 weeks. Also disclosed herein is a method of detecting an rs12979860 single nucleotide polymorphism (SNP) in a hepatitis C virus (HCV) infected patient comprising: detecting the rs12979860 SNP of chromosome 19 in a biological sample from a patient, wherein an rs12979860 SNP C/C patient is administered an abbreviated treatment regimen with a direct-acting antiviral agent in combination with peginterferon alfa-2a and ribavirin; and wherein the abbreviated HCV treatment regimen is less than 48 weeks. | 2012-05-03 |
| 20120107279 | PREVENTION AND TREATMENT OF ROTAVIRUS DIARRHOEA - This invention relates to | 2012-05-03 |
| 20120107280 | BIOFUNGICIDAL COMPOSITION FOR CONTROLLING PHYTOPATHOGENIC FUNGI - Biofungicide composition derived from a biologically pure culture of a Chilean bacterial isolate obtained from the skin of grapes, corresponding to | 2012-05-03 |
| 20120107281 | COMPOSITIONS AND METHODS FOR MODIFYING CELL SURFACE GLYCANS - Methods and compositions for modifying glycans (e.g., glycans expressed on the surface of live cells or cell particles) are provided herein. | 2012-05-03 |
| 20120107282 | NEURAL STEM CELL COMPOSITION CAPABLE OF TREATING CANCER AND METHOD OF TREATMENT - Disclosed is a method of treatment of an individual suffering from primary brain tumors (glioma and medulloblastoma) and brain metastases of extracranial cancers using human stem cells encoding therapeutic genes. The method includes giving the individual a clinically acceptable therapeutic reagent by intravascular injection of a pharmaceutical composition. The pharmaceutical composition includes neural stem cells (NSCs) genetically engineered to express a suicide gene (cytosine deaminase) and a cytokine gene (IFN-β) and a pharmaceutical carrier suitable for injection. The NSCs migrate selectively to tumor site in the brain, target tumor cells, kill tumor cells, inhibit tumor growth and thus treat the tumor. | 2012-05-03 |
| 20120107283 | HUMAN SKIN EQUIVALENTS EXPRESSING EXOGENOUS POLYPEPTIDES - The present invention relates generally to compositions for wound closure. More specifically, the present invention provides human skin equivalents engineered to express exogenous polypeptides (e.g., antimicrobial polypeptides and keratinocyte growth factor 2) and compositions and methods for making human skin equivalents engineered to express exogenous polypeptides. In addition, the present invention provides methods for treatment of wounds with human skin equivalents engineered to express exogenous polypeptides. | 2012-05-03 |
| 20120107284 | Stem cells for transplantation and methods for production thereof - A medicament for cell differentiation to alleviate cell and cell-related deficiencies in a mammal is described. The medicament comprises in two or more parts in vitro produced non-activated inducible gene construct(s) capable of expressing transcription factor(s), and optionally additional suppressor(s) or activator(s) of expression of said transcription factor(s), in a cell for transfection, such as a stem cell, and separate exogenous inducer(s) for in vivo expression, such as tetracycline, streptogramin and macrolide. Examples of the cell and cell-related deficiencies are traumatic injuries to the brain and spinal cord, neurodegenerative disorders, stroke, demyelinating disorders, neuropathic pain disorders, diabetes, myocardial infarction, skeletal muscle disorders. Further, a delivery system for delivery of the medicament to a mammal as well as a method of treating cell and cell-related deficiencies in a mammal, are described. | 2012-05-03 |
| 20120107285 | Mitochondrial enhancement of cells - Certain embodiments disclosed herein include, but are not limited to, at least one of compositions, methods, devices, systems, kits, or products regarding rejuvenation or preservation of stem cells. Certain embodiments disclosed herein include, but are not limited to, methods of modifying stem cells, or methods of administering modified stem cells to at least one biological tissue. | 2012-05-03 |
| 20120107286 | PLURIPOTENT STEM CELLS - Methods and compositions for the generation and use of footprint-free human induced pluripotent stem cells are provided. | 2012-05-03 |
| 20120107287 | SPECIALIZED MEDICAL NUTRITION FOR SURGICAL AND TRAUMA PATIENTS CONTAINING PROBIOTICS - The present invention relates to the field of specialized nutritional compositions. In particular, the present invention provides nutritional compositions for providing complete nutrition to hospitalized patients comprising probiotic micro-organisms. Such probiotic micro-organisms may be non-replicating micro-organisms, such as bioactive heat-treated probiotic micro-organisms, for example. | 2012-05-03 |
| 20120107288 | COMPOSITIONS AND METHODS FOR INHIBITING PATHOGENIC GROWTH - The invention includes methods and compositions for treating an animal to inhibit the incidence and growth of | 2012-05-03 |
| 20120107289 | Lactic Bacteria and Their Use in the Prevention of Diarrhea - The present invention concerns a lactic composition useful for the prevention or treatment of diarrhea such as antibiotic associated diarrhea or “tourista.” The composition according to the invention contains at least a bacterial strain selected from the group consisting of | 2012-05-03 |
| 20120107290 | NON-REPLICATING MICRO-ORGANISMS AND THEIR IMMUNE BOOSTING EFFECT - The present invention generally relates to the field of probiotic bacteria. In particular, the present invention conceras non-replicating probiotics, such as the genus Lactobacillus, Bifidobacterium or combinations thereof, for example | 2012-05-03 |
| 20120107291 | Bifidobacteria for treating diabetes and related conditions - This invention relates to new uses of Bifidobacteria (particularly, although not exclusively, probiotic Bifidobacteria), and to food products, feed products, dietary supplements and pharmaceutical formulations containing them. The bacteria are suitable for the treatment of diabetes (particularly Type 2 diabetes), obesity and related conditions, metabolic syndrome, insulin resistance, and impaired glucose metabolism and consequences thereof, lowering tissue inflammation, treating hepatitis, myositis and cardiovascular conditions. | 2012-05-03 |
| 20120107292 | METHOD FOR THE SIMULTANEOUS INDUCTION OF CTL AND gamma-delta T CELL - Disclosed are: a method for culture of disease antigen specific CTLs and γδT cells in one culture step conveniently and efficiently; and a pharmaceutical agent and a therapeutic/prophylactic method both of which use a cell produced by the method. Blood is collected and peripheral blood mononuclear cells are separated from the blood. Aminobisphosphonate and a disease antigen are added to the peripheral blood mononuclear cells at the beginning of culture, and the cell culture is carried out for a predetermined period to proliferate/induce disease antigen specific CTLs and γδT cells simultaneously until the numbers of the cells reach values that are effective for the treatment of a disease. The CTLs and the γδT cells thus produced are used for the treatment. | 2012-05-03 |
| 20120107293 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER - A method of treating cancer comprises: (a) providing allogenic or autologous white blood cells from a suitable donor; and then (b) administering the white blood cells to the subject in an amount effective to treat the cancer. Preferably the white blood cells comprise innate immune cells. Preferably the white blood cells comprise less than 10% by number of cytotoxic T lymphocytes. Preferably the white blood cells, or more particularly the innate immune cells, are preselected in vitro to kill cancer cells in vitro (for example, by collecting white blood cells from the patient and determining that the white blood cells kill cancer cells in vitro before and thereby pre-selecting the donor, before collecting a subsequent population of cells from the donor for administration). | 2012-05-03 |
| 20120107294 | COMPOSITION FOR IN VIVO TRANSPLANTATION FOR TREATMENT OF HUMAN CERVICAL CANCER COMPRISING MONONUCLEAR CELLS DERIVED FROM UMBLICAL CORD BLOOD - Provided is a composition for in vivo transplantation for the treatment of human cervical cancer, comprising mononuclear cells derived from umbilical cord blood and a pharmaceutically acceptable carrier. When the umbilical cord blood-derived mononuclear cells are transplanted in vivo, cervical cancer can be effectively treated. In particular, the mononuclear cells derived from the umbilical cord blood retain high differentiation and proliferation abilities and exhibit very low graft-versus-host (GVH) reactions which are side effects caused by transplantation, and thus, can be transplanted to many patients. | 2012-05-03 |
| 20120107295 | Methods and Compositions for Detecting Pancreatic Disease - Methods and compositions for at least determining whether a human subject has a pancreatic disease are provided. In practicing the subject methods, a sample from a subject is assayed for a pancreatic glycoprotein (GP2) analyte to determine whether the subject at least has the pancreatic disease. Also provided are kits, systems, and devices for practicing the subject methods. | 2012-05-03 |
| 20120107296 | FEED SUPPLEMENT - The present invention relates to a feed supplement comprising a phytase and a lipolytic enzyme, wherein said lipolytic enzyme has lipase activity at a pH in the range of about pH1.5 to about pH3.5. | 2012-05-03 |
| 20120107297 | Method for therapeutic angiogenesis - The present invention relates to the E2 | 2012-05-03 |
| 20120107298 | Use of LCAT for Treating Anemia and Red Blood Cell Dysfunction - Disclosed are methods for treating conditions characterized by anemia or red blood cells dysfunction by administering an agent that increases the level of endogenous LCAT or LCAT activity. Additionally disclosed are methods of treating conditions wherein red blood cells have reduced function in relation to deformability, oxygenation, increased adhesion and aggregability, reduced nitric oxide function, or decreased life-span, increased free cholesterol, or abnormal phospholipid content. Also disclosed are methods for treating conditions characterized by an abnormal concentration of free cholesterol in red blood cells and methods of normalizing the free cholesterol content of red blood cells. | 2012-05-03 |
| 20120107299 | PHOSPHORYLATION-INHIBITING AGENT OR DEPHOSPHORYLATING AGENT FOR PTEN - Provided is a preventive, progression inhibitor or remedy for a disease one of the causes of which is the activation of the P13K/AKT signaling pathway or vice versa. A phosphorylation-inhibiting and/or dephosphorylating agent, which has an effect of inhibiting the phosphorylation at least at one of the phosphorylation sites of PTEN protein selected from the group consisting of T382, T383 and S380 and/or an effect of dephosphorylating the same, is prepared. Alternatively, a phosphorylation-inhibiting or dephosphorylating agent for PTEN is screened by a method comprising a step for confirming an ability of a test substance to inhibit the phosphorylation at least at one of the phosphorylation sites of PTEN protein selected from the group consisting of T382, T383 and S380 or a dephosphorylation ability thereof. Then, a substance having an effect opposite to the inhibition of PTEN phosphorylation or dephosphorylation thereof, e.g., an antibody against the phosphorylation-inhibiting or dephosphorylating agent for PTEN obtained above, is also obtained. | 2012-05-03 |
| 20120107300 | Cannabinoid Compositions and Methods - Cannabinoid compositions and methods of administering said cannabinoid compositions are disclosed. The cannabinoid compositions disclosed herein include compounds which have been strategically selected to eliminate, or least mitigate, one of the negative side effects associated with consuming cannabinoids. A daytime formula includes compounds aimed at nullifying the negative side effects that cannabinoid consumption has on a patient's daily operations and activities. A nighttime formula includes compounds aimed at nullifying the negative side effects that cannabinoid consumption has a patient's sleep. | 2012-05-03 |
| 20120107301 | METHOD OF TREATING AUTOIMMUNE DISEASE BY INDUCING ANTIGEN PRESENTATION BY TOLERANCE INDUCING ANTIGEN PRESENTING CELLS - Antibodies to antigen presenting cells may be utilized to interfere with the interaction of the antigen presenting cell and immune cells, including T cells. Peptides may be linked to said antibodies thereby generating an immune response to such peptides. Preferably peptides linked to the antibodies are associated with autoimmunity. | 2012-05-03 |
| 20120107302 | COMBINATIONS OF AN ANTI-HER2 ANTIBODY-DRUG CONJUGATE AND CHEMOTHERAPEUTIC AGENTS, AND METHODS OF USE - Combinations of the antibody-drug conjugate trastuzumab-MCC-DM1 and chemotherapeutic agents, including stereoisomers, geometric isomers, tautomers, solvates, metabolites and pharmaceutically acceptable salts thereof, are useful for inhibiting tumor cell growth, and for treating disorders such as cancer mediated by HER2 and KDR (VEGFR receptor 1). Methods of using such combinations for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed. | 2012-05-03 |
| 20120107303 | SYNERGISTIC TREATMENT OF CANCER USING IMMUNOMERS IN CONJUNCTION WITH CHEMOTHERAPEUTIC AGENTS - The invention relates to the therapeutic use of immunostimulatory oligonucleotides and/or immunomers in combination with chemotherapeutic agents to provide a synergistic therapeutic effect. | 2012-05-03 |
| 20120107304 | Combination therapy in treatment of oncological and fibrotic diseases - The invention relates to new methods for the treatment of oncological and fibrotic disease comprising the combined administration of a cell signalling and/or angiogenesis inhibitor in conjunction with an Aurora kinase inhibitor. | 2012-05-03 |
| 20120107305 | Combination Therapy - The present invention relates to a method for the production of an antiangiogenic and/or vascular permeability reducing effect in a warm-blooded animal such as a human which is optionally being treated with ionising radiation, particularly a method for the treatment of a cancer, particularly a cancer involving a solid tumour, which comprises the administration of ZD6474 in combination with bevacizumab; to a pharmaceutical composition comprising ZD6474 and bevacizumab; to a combination product comprising ZD6474 and bevacizumab for use in a method of treatment of a human or animal body by therapy; to a kit comprising ZD6474 and bevacizumab; to the use of ZD6474 and bevacizumab in the manufacture of a medicament for use in the production of an antiangiogenic and/or vascular permeability reducing effect in a warm-blooded animal such as a human which is optionally being treated with ionising radiation. | 2012-05-03 |
| 20120107306 | ANTIBODIES FOR EPIDERMAL GROWTH FACTOR RECEPTOR 3 (HER3) - The present invention relates to antibodies or fragments thereof that target a conformational epitope of a HER receptor. In particular, the invention relates to antibodies or fragments thereof that target a conformational epitope of HER3 receptor and compositions and methods of use thereof. | 2012-05-03 |
| 20120107307 | DIHYDROPYRIDIN SULFONAMIDES AND DIHYDROPYRIDIN SULFAMIDES AS MEK INHIBITORS - This invention concerns N-(ortho phenylamino dihydropyridyl)sulfonamides and N-(ortho phenylamino dihydropyridyl), N′-alkyl sulfamides which are inhibitors of MEK and are useful in the treatment of cancer and other hyperproliferative diseases. | 2012-05-03 |
| 20120107308 | GENE EXPRESSION LEVELS OF EGFR, VEGFR2, AND ERCC1 ASSOCIATED WITH CLINICAL OUTCOMES OF CHEMOTHERAPY - The invention provides compositions and methods for identifying a cancer patient suitable for anti-VEGF therapy. After determining if a patient is likely to be successfully treated, the invention also provides methods for treating the patients. | 2012-05-03 |
| 20120107309 | POLYMORPHISM IN K-RAS 3' UNTRANSLATED REGION ASSOCIATED WITH CLINICAL OUTCOMES OF CANCER TREATMENTS INDEPENDENT OF K-RAS MUTATION STATUS - The invention provides compositions and methods for determining the likelihood of response or survival of cancer patients treated with anti-EGFR therapy, topoisomerase inhibitor therapy or anti-EGFR therapy/topoisomerase inhibitor therapy combination therapy. After determining if a patient is likely to be successfully treated, the invention also provides methods for treating the patients. | 2012-05-03 |
| 20120107310 | METHODS OF ANTAGONIZING SIGNAL TRANSDUCTION IN SPINAL CORD CELLS - Use of antagonists to IL-31 are used to treat inflammation and pain by inhibiting, preventing, reducing, minimizing, limiting or minimizing stimulation in neuronal tissues. Such antagonists include antibodies and fragments, derivative, or variants thereof. Symptoms such as pain, tingle, sensitization, tickle associated with neuropathies are ameliorated. | 2012-05-03 |
| 20120107311 | TARGETED IDENTIFICATION OF IMMUNOGENIC PEPTIDES - This invention relates generally to identifying peptide sequences involved in antibody binding to any protein for synthesis of vaccine treatments. This novel method allows for a more manageable vaccine peptide discovery and specific generation of unique immunogenic peptides from self-tumor associated proteins and/or foreign proteins from infectious organisms for specific and/or enhanced expression only in the presence of the antibody. | 2012-05-03 |
| 20120107312 | Combinations for the Treatment of Diseases involving Cell Proliferation - Disclosed are pharmaceutical compositions for the treatment of diseases which involve cell proliferation. Also disclosed are methods for the treatment of said diseases, comprising co-administration of a compound 1 of Formula (I) | 2012-05-03 |
| 20120107313 | MAMMALIAN RECEPTOR PROTEINS; RELATED REAGENTS AND METHODS - Nucleic acids encoding mammalian, e.g., primate, receptors, purified receptor proteins and fragments thereof. Antibodies, both polyclonal and monoclonal, are also provided. Methods of using the compositions for both diagnostic and therapeutic utilities are described. | 2012-05-03 |
| 20120107314 | CAB MOLECULES - The present invention relates to CAB molecules, ADEPT constructs directed against CEA, and their use in therapy. | 2012-05-03 |
| 20120107315 | Predicting progression to advanced age-related macular degeneration using a polygenic score - The present invention relates to methods for identifying individuals with intermediate age-related macular degeneration (AMD) who possess a greater risk of progression to advanced AMD, using a polygenic score calculated based on the results of genome-wide gene association studies, using thousands of single-nucleotide polymorphisms (SNPs). | 2012-05-03 |
